PPT-EFFECTS ON RENAL FUNCTION OF A SWITCH FROM TENOFOVIR (TDF)

M Harris S Guillemi K Chan B Yip M Hull V Dias Lima R Hogg J Montaner Abstract WEAB0202 Organ Dysfunction in HIV Its Complicated Wednesday 3 July 2013 143016 00 Session . An HIV pre-exposure prophylaxis trial in Thailand: . participant adherence and study results . National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of HIV/AIDS Prevention. A collaborative project involving: The Bangkok Metropolitan Administration, the. SPARE . Study. SPARE Study: switch to DRV/r + RAL . Design. Age ≥ . 20. years. HIV+. HIV-1 RNA. < 50 c/ml > 15 weeks. On LPV/r + TDF/FTC. No prior . virologic. failure. on PI/r- or INSTI-containing regimen. STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (mITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -12%, 85% power. If non-inferiority and lower margin > 0, assessment for superiority. Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, Frontier AETC ECHO. October 2015. ID Week Review 2015. 1) Switching from TDF to TAF. 2) Simplifying salvage therapy to E/C/F/TAF + DRV. A.Dravid. 1. ,A.Sadre. 2. ,S.Dhande. 1. , A.Borkar. 1. ,M.Kulkarni. 1. ,M.Dravid. 3. 1. . Ruby hall clinic, Department of HIV Medicine, . Pune. , India. 2. Ruby hall clinic, Department of Nephrology, . Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 2nd Quarter. July-September 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. GS-US-292-0109 Study. GS-US-311-1089 Study. . Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (ITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -10%, > 95% power. TOTEM. Switching the NRTI Backbone to Tenofovir DF-Emtricitabine. TOTEM: Study Design. Source. : . Valantin. MA, et al. . J . Antimicrob. . Chemother. . 2010;65:556-61.. TDF-FTC + Continue . 3. rd. STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. ADONE Trial. Simplification to Efavirenz-Tenofovir DF-Emtricitabine . ADONE: Study Design. Source: . Airoldi. M, et al. Patient Prefer Adherence. 2010;4:115-25.. Study Design: ADONE Study . Background. Study 105. Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2). Study 105: Study Design. Source: . Elion. R, et al. AIDS. 2011;25:1881-6. . Background. : Randomized, partially placebo-controlled, double-blind phase 2 trial to compare the safety and efficacy of cobicistat and ritonavir as pharmacokinetic enhancers administered with atazanavir and fixed-dose tenofovir DF-emtricitabine in treatment-naïve adults with HIV infection. SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEET: Study Design. Source: Fisher M, et al. . J Acquir Immune Defic Syndr. 2009;51:562-8.. Background. : Randomized, . controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed . Tenofovir. . Disoproxil. . Fumarate. to . Tenofovir. . Alafenamide. Have Improved Renal and Bone Safety through 48 Weeks. Study GS-US-292-0112. Samir K. Gupta. 1. , Anton Pozniak. 2. , Jose Arribas.